Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali
Antiviral Therapy, Volume 12, No. 1, Year 2007
Notification
URL copied to clipboard!
Description
Objective: To determine the genetic diversity of HIV-1 reverse transcriptase (RT) and protease sequences and the presence of mutations linked to antiretroviral (ARV) resistance in treatment-naive, HIV-1-infected individuals living in Mali. Methods: Ninety-eight samples from ARV drug-naive, HIV-1-infected patients were collected in one clinical centre in Bamako, Mali in 2005. RT and protease genes were sequenced in order to perform phylogenetic and resistance analyses. Results: The most prevalent subtype was CRF02-AG (75% of cases), followed by the CRF06-cpx subtype (20%). Intersubtype recombinants between CRF02-AG, CRF01-AE and CRF06-cpx were also described in 5% of cases. After 4 years of ARV use in Mali, two previously untreated individuals (2%; 95% CI: 0.00-4.77%) were found to have resistant viruses, one with a single nucleoside mutation and one with K103N non-nucleoside reverse transcriptase inhibitor resistance mutation. No evidence of transmitted protease inhibitor resistance mutations was found. Conclusion: These data provide direct evidence for the circulation of HIV-1 isolates containing resistance mutations in treatment-naive patients in Mali. Since ARV use in Mali began, more than 5,000 patients have started treatment, mostly with Triomune (stavudine/lamivudine/ nevirapine). The resistance-associated mutations detected in the present study are consistent with this treatment regimen. Continued surveillance will be required to monitor the emergence of ARV resistance in this country. © 2007 International Medical Press.
Authors & Co-Authors
Derache, Anne
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Traore, Ousmane
Mali, Bamako
Centre D'ecoute de Soins
Koita, Victoria
Mali, Bamako
Centre D'ecoute de Soins
Sylla, Aliou O.
Mali, Bamako
Centre D'ecoute de Soins
Mali, Bamako
Cellule Multisectorielle de Lutte Contre le Sida
Tubiana, Roland
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Simon, Anne Laure
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Canestri, Ana
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Carcelain, Guislaine
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Katlama, Christine
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Calvez, Vincent
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Cissé, Mamadou C.
Mali, Bamako
Centre D'ecoute de Soins
Marcelin, Anne Geneviève
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Statistics
Citations: 12
Authors: 12
Affiliations: 3
Identifiers
ISSN:
13596535
Research Areas
Cancer
Genetics And Genomics
Infectious Diseases
Study Locations
Mali